EMBC vs NVO
EMBC: A dedicated diabetes care company specializing in insulin delivery systems and pen needles for millions of users worldwide. NVO: A leading global healthcare company with a heritage in diabetes, pioneering scientific breakthroughs to defeat serious chronic diseases through innovative medicines and expanded access.
Side-by-side fundamentals
| Metric | EMBC | NVO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.25 | $48.19 | |
| Market cap as of 2026-07-23 | $193M | $219.8B | |
| P/E as of 2026-07-23 | 1.72 | 11.78 | EMBC lower |
| PEG as of 2026-07-23 | -0.17 | 16.16 | EMBC lower |
| Net margin as of 2026-07-23 | +10.7% | +37.2% | NVO higher |
| Gross margin as of 2026-07-23 | +61.9% | +81.8% | NVO higher |
| Operating margin as of 2026-07-23 | +25.8% | +45.3% | NVO higher |
| ROE as of 2026-07-23 | +6.1% | +66.4% | NVO higher |
| ROA as of 2026-07-23 | +10.3% | +23.3% | NVO higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.72 | EMBC lower |
| Revenue growth (YoY) as of 2026-07-23 | -3.4% | +8.1% | NVO higher |
| Revenue CAGR (3y) SEC XBRL | -1.5% | n/a | |
| Dividend yield as of 2026-07-23 | +1.2% | +3.7% | NVO higher |
| Dividend streak (yrs) SEC XBRL | 4 | n/a | |
| Beta as of 2026-07-23 | 0.84 | 1.85 | |
| 1-year return as of 2026-07-22 close | -67.2% | -23.8% | NVO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.